{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is AlloVir, Inc. technically bullish or bearish?
As of June 13, 2025, the technical trend has shifted to a bearish stance, supported by bearish MACD, Bollinger Bands, and moving averages, despite a bullish RSI on the weekly chart.
Who are in the management team of AlloVir, Inc.?
As of March 2022, the management team of AlloVir, Inc. includes CEO David Hallal, President and CFO Vikas Sinha, and several directors: Juan Vera, Jeffrey Bornstein, Diana Brainard, Malcolm Brenner, and Ansbert Gadicke. They oversee the company's strategic direction and operations.
What does AlloVir, Inc. do?
AlloVir, Inc. is a late clinical-stage cell therapy company focused on developing allogeneic T cell therapies for viral diseases, with a market cap of approximately $47.88 million and a net profit of -$10 million as of March 2025. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.
How big is AlloVir, Inc.?
As of Jun 18, AlloVir, Inc. has a market capitalization of 47.88 million and reported net sales of 0.00 million with a net profit of -38.68 million for the latest four quarters. Shareholder's funds are 113.31 million, and total assets amount to 118.55 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
